Why pharma sees potential in marijuana, and the hurdles it needs to overcome
The United
States’ conflicted history with marijuana regulation has caused it to
lag behind countries such as Israel and Canada in developing
pharmaceutical-grade drugs based on cannabis. But as public support has
grown in California, a number of cannabis biotech companies are setting
up shop with an eager eye on the future. More than half of all
investments in the marijuana industry are now going to biotech companies
seeking the “next billion-dollar drug,” according to an investment
analyst. But will there be a market for cannabis-derived pills, powders
and syrups? Many medical marijuana users view cannabis as a holistic
alternative to pharmaceuticals.
No comments:
Post a Comment